Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global trial of PTG-300 in patients with myelodysplastic syndrome (MDS)

Trial Profile

Global trial of PTG-300 in patients with myelodysplastic syndrome (MDS)

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs PTG 300 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2017 New trial record
    • 14 Dec 2017 According to a Protagonist Therapeutics media release, discussion with health authorities regarding Investigational New Drug (IND) application and ex-U.S. clinical trial applications is expected in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top